标题
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
作者
关键词
-
出版物
Frontiers in Endocrinology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-01-12
DOI
10.3389/fendo.2021.791633
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma
- (2021) Yona Greenman et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- β-arrestin 2 is required for dopamine receptor type 2 inhibitory effects on AKT phosphorylation and cell proliferation in pituitary tumors
- (2020) Federica Mangili et al. NEUROENDOCRINOLOGY
- The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists
- (2020) Zerui Wu et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
- (2019) Maria Caroline Alves Coelho et al. Scientific Reports
- Dopamine Agonists - from the 1970s up to today
- (2019) Renata Auriemma et al. NEUROENDOCRINOLOGY
- miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma
- (2019) Bin Hu et al. BRAIN RESEARCH BULLETIN
- Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study
- (2019) Annamaria Colao et al. Endokrynologia Polska
- Dopamine agonist resistant prolactinomas: any alternative medical treatment?
- (2019) P. Souteiro et al. Pituitary
- Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands
- (2018) Leandro Kasuki et al. CLINICAL ENDOCRINOLOGY
- Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma
- (2018) Bin Hu et al. BRAIN RESEARCH
- MicroRNA-93 mediates cabergoline-resistance by targeting ATG7 in prolactinoma
- (2018) Zerui Wu et al. JOURNAL OF ENDOCRINOLOGY
- Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis
- (2018) R. Palui et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Dopamine Agonists for Pituitary Adenomas
- (2018) Odelia Cooper et al. Frontiers in Endocrinology
- Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma
- (2018) Rafael L. Batista et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Management of dopamine agonist-resistant prolactinoma
- (2018) Dominique Maiter NEUROENDOCRINOLOGY
- Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1
- (2018) M. Jian et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors
- (2017) E. Peverelli et al. INTERNATIONAL JOURNAL OF CANCER
- BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas
- (2017) Alejandro Ibáñez-Costa et al. Scientific Reports
- Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation
- (2016) E. Peverelli et al. CANCER LETTERS
- Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists
- (2016) Y Greenman et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Cabergoline for Cushing’s disease: a large retrospective multicenter study
- (2016) A Ferriere et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas
- (2016) Roberto Würth et al. MOLECULAR NEUROBIOLOGY
- Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas andin vivoresponse to cabergoline therapy
- (2015) Leonardo Vieira Neto et al. CLINICAL ENDOCRINOLOGY
- The Treatment of Cushing's Disease
- (2015) Rosario Pivonello et al. ENDOCRINE REVIEWS
- Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
- (2015) Lynnette K. Nieman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline
- (2015) Shao Jian Lin et al. Oncotarget
- Acromegaly: An Endocrine Society Clinical Practice Guideline
- (2014) Laurence Katznelson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MicroRNA expression profile of bromocriptine-resistant prolactinomas
- (2014) Zhe Bao Wu et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Expert consensus document: A consensus on the medical treatment of acromegaly
- (2014) Andrea Giustina et al. Nature Reviews Endocrinology
- β-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients With Acromegaly
- (2013) Federico Gatto et al. ENDOCRINOLOGY
- Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation
- (2013) J. Hausser et al. GENOME RESEARCH
- Each Individual Isoform of the Dopamine D2 Receptor Protects from Lactotroph Hyperplasia
- (2013) Daniela Radl et al. MOLECULAR ENDOCRINOLOGY
- Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?
- (2013) M. Barbot et al. Pituitary
- Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial
- (2012) C. E. Higham et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Filamin-A Is Essential for Dopamine D2 Receptor Expression and Signaling in Tumorous Lactotrophs
- (2012) Erika Peverelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC
- (2012) Marc R Fabian et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The role of somatostatin and dopamine D2 receptors in endocrine tumors
- (2011) Federico Gatto et al. ENDOCRINE-RELATED CANCER
- Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels
- (2011) Satoko Shimazu et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
- (2011) Shlomo Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Place of Cabergoline in Acromegaly: A Meta-Analysis
- (2011) Laure Sandret et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Medical treatment of prolactinomas
- (2011) Annamaria Colao et al. Nature Reviews Endocrinology
- The Physiology, Signaling, and Pharmacology of Dopamine Receptors
- (2011) J.-M. Beaulieu et al. PHARMACOLOGICAL REVIEWS
- Dopamine-Induced Apoptosis of Lactotropes Is Mediated by the Short Isoform of D2 Receptor
- (2011) Daniela Betiana Radl et al. PLoS One
- VEGF and CD31 Association in Pituitary Adenomas
- (2010) Carolina Cristina et al. ENDOCRINE PATHOLOGY
- Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior
- (2010) Zhe Bao Wu et al. JOURNAL OF NEURO-ONCOLOGY
- Agonist-Induced Endocytosis and Receptor Phosphorylation Mediate Resensitization of Dopamine D2Receptors
- (2010) Dongim Cho et al. MOLECULAR ENDOCRINOLOGY
- A Dopamine D1 Receptor-Dependent β-Arrestin Signaling Complex Potentially Regulates Morphine-Induced Psychomotor Activation but not Reward in Mice
- (2010) Nikhil M Urs et al. NEUROPSYCHOPHARMACOLOGY
- Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease
- (2010) Richard A. Feelders et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma
- (2010) M. Alberiche Ruano et al. Pituitary
- PARP-1 is involved in autophagy induced by DNA damage
- (2009) José Antonio Muñoz-Gámez et al. Autophagy
- The dopamine–somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways
- (2009) Erika Peverelli et al. CANCER LETTERS
- Invasive Giant Prolactinoma with Loss of Therapeutic Response to Cabergoline: Expression of Angiogenic Markers
- (2009) María Susana Mallea-Gil et al. ENDOCRINE PATHOLOGY
- New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites
- (2009) I. Lee et al. GENOME RESEARCH
- G Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2Dopamine Receptor
- (2009) Yoon Namkung et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly
- (2009) Leonardo Vieira Neto et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review
- (2009) L. A. Behan et al. Pituitary
- Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease
- (2009) Lucio Vilar et al. Pituitary
- Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
- (2008) T. Florio et al. ENDOCRINE-RELATED CANCER
- Correlation ofin Vitroandin VivoSomatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy
- (2008) Diego Ferone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Genes Differentially Expressed in Prolactinomas Responsive and Resistant to Dopamine Agonists
- (2008) Vanessa Q. Passos et al. NEUROENDOCRINOLOGY
- Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas
- (2008) M Filopanti et al. PHARMACOGENOMICS JOURNAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started